Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENSC NASDAQ:MYNZ NASDAQ:VIVS NASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENSCEnsysce Biosciences$0.36-2.2%$0.50$0.31▼$2.75$3.36M0.874.31 million shs91,460 shsMYNZMainz Biomed$0.37-3.1%$0.61$0.55▼$4.43$3.34M0.31371,589 shs314,604 shsVIVSVivoSim Labs$1.40-1.1%$1.67$1.25▼$5.30$3.64M1.411.17 million shs4,993 shsWINTWindtree Therapeutics$0.02-6.5%$0.01$0.01▼$1.86$846K1.75402,955 shs54,789 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENSCEnsysce Biosciences-5.13%-0.43%-35.78%-19.81%-82.15%MYNZMainz Biomed+4.37%-16.85%-20.04%-59.82%-84.68%VIVSVivoSim Labs0.00%-1.40%-12.96%-38.16%+140,999,900.00%WINTWindtree Therapeutics+1.95%-16.40%+90.00%+109.00%-97.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENSCEnsysce Biosciences$0.36-2.2%$0.50$0.31▼$2.75$3.36M0.874.31 million shs91,460 shsMYNZMainz Biomed$0.37-3.1%$0.61$0.55▼$4.43$3.34M0.31371,589 shs314,604 shsVIVSVivoSim Labs$1.40-1.1%$1.67$1.25▼$5.30$3.64M1.411.17 million shs4,993 shsWINTWindtree Therapeutics$0.02-6.5%$0.01$0.01▼$1.86$846K1.75402,955 shs54,789 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENSCEnsysce Biosciences-5.13%-0.43%-35.78%-19.81%-82.15%MYNZMainz Biomed+4.37%-16.85%-20.04%-59.82%-84.68%VIVSVivoSim Labs0.00%-1.40%-12.96%-38.16%+140,999,900.00%WINTWindtree Therapeutics+1.95%-16.40%+90.00%+109.00%-97.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENSCEnsysce Biosciences 1.00SellN/AN/AMYNZMainz Biomed 1.50ReduceN/AN/AVIVSVivoSim Labs 1.00SellN/AN/AWINTWindtree Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest WINT, ENSC, VIVS, and MYNZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026ENSCEnsysce Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/6/2026MYNZMainz Biomed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENSCEnsysce Biosciences$5.07M0.66N/AN/A$0.63 per share0.57MYNZMainz Biomed$659.94K5.05N/AN/A$2.61 per share0.14VIVSVivoSim Labs$142K25.62N/AN/A$5.54 per share0.25WINTWindtree TherapeuticsN/AN/AN/AN/A$0.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENSCEnsysce Biosciences-$10.18M-$4.22N/AN/AN/A-200.87%-426.62%-195.53%5/12/2026 (Estimated)MYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/AVIVSVivoSim Labs-$2.48M-$3.15N/AN/AN/A-861.27%-15.51%-11.31%N/AWINTWindtree Therapeutics-$1.79M-$8.77N/AN/AN/AN/A-207.34%-50.19%5/14/2026 (Estimated)Latest WINT, ENSC, VIVS, and MYNZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ENSCEnsysce Biosciences-$0.73N/AN/AN/A$1.90 millionN/A3/30/2026Q4 2025ENSCEnsysce Biosciences-$1.26-$0.75+$0.51-$0.75$0.50 million$1.88 million2/11/2026Q3 2025VIVSVivoSim LabsN/A-$1.03N/A-$1.03N/A$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENSCEnsysce BiosciencesN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENSCEnsysce BiosciencesN/A1.591.59MYNZMainz Biomed0.440.520.43VIVSVivoSim LabsN/A2.442.44WINTWindtree TherapeuticsN/A0.430.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENSCEnsysce Biosciences5.63%MYNZMainz BiomedN/AVIVSVivoSim Labs8.23%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipENSCEnsysce Biosciences2.80%MYNZMainz Biomed18.20%VIVSVivoSim Labs2.50%WINTWindtree Therapeutics0.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENSCEnsysce Biosciences109.28 million9.02 millionNot OptionableMYNZMainz Biomed309.06 million7.41 millionNot OptionableVIVSVivoSim Labs202.61 million2.54 millionN/AWINTWindtree Therapeutics3044.99 million3.66 millionNot OptionableWINT, ENSC, VIVS, and MYNZ HeadlinesRecent News About These CompaniesWindtree Therapeutics Delays Filing of Annual ReportApril 1, 2026 | tipranks.comCommLoan Achieves Nationwide Regulatory Approval Across All 50 StatesMarch 17, 2026 | prnewswire.comWindtree Therapeutics Announces Sudden Departure of President and COOJanuary 17, 2026 | theglobeandmail.comWindtree sells heart drug assets, keeps a cut of any future breakthroughDecember 30, 2025 | msn.comWindtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug CandidatesDecember 23, 2025 | finance.yahoo.comWindtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech SpaceDecember 4, 2025 | markets.businessinsider.comWindtree announces it has signed a letter of intent to acquire CommLoanDecember 4, 2025 | msn.comWindtree Expands Global Patent Portfolio as Heart Failure Pipeline Gains MomentumNovember 20, 2025 | msn.comWindtree may receive license agreement payments for renewed development workNovember 17, 2025 | msn.comWindtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the LicenseeNovember 17, 2025 | finance.yahoo.comWindtree Therapeutics announces patents allowed in Canada, MexicoNovember 14, 2025 | msn.comWindtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent EstateNovember 14, 2025 | markets.businessinsider.comWindtree Therapeutics Delays Quarterly Report FilingNovember 14, 2025 | tipranks.comWindtree Therapeutics Signs Letter of Intent with TESI for $7.5 Million Cash and Securities AgreementNovember 13, 2025 | quiverquant.comQWindtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services CompanyNovember 13, 2025 | globenewswire.comWindtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services CompanyNovember 13, 2025 | globenewswire.comWindtree Therapeutics Approves Key Financial Structure ChangesSeptember 3, 2025 | msn.comWindtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder MeetingSeptember 2, 2025 | markets.businessinsider.comWindtree Therapeutics, Inc. Stockholders Approve Strategic Shift Toward Environmental Services and Biotech PartnershipsSeptember 2, 2025 | quiverquant.comQWarrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ DelistingAugust 27, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWINT, ENSC, VIVS, and MYNZ Company DescriptionsEnsysce Biosciences NASDAQ:ENSC$0.36 -0.01 (-2.16%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Mainz Biomed NASDAQ:MYNZ$0.37 -0.01 (-3.11%) As of 05/7/2026Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.VivoSim Labs NASDAQ:VIVS$1.40 -0.02 (-1.06%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.Windtree Therapeutics NASDAQ:WINT$0.02 0.00 (-6.47%) As of 10:17 AM EasternWindtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
